Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug-drug Interaction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Drug-drug Interaction. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-000363-24 Sponsor Protocol Number: Met-Dipy001 Start Date*: 2012-04-18
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: The effect of dipyridamole on the pharmacokinetics of metformin.
    Medical condition: The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or s...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10068071 Inhibitory drug interaction PT
    14.1 10018065 - General disorders and administration site conditions 10013710 Drug interaction PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-003275-42 Sponsor Protocol Number: MEC-2021-0478 Start Date*: 2023-04-13
    Sponsor Name:
    Full Title: The influence of different DIets on ALECTinib pharmacokinetics in NSCLC patients; the DIALECT study.
    Medical condition: Weight gain is a common side effect of alectinib therapy. Semaglutide could be used as medical anti-obesity drug to prevent alectinib-induced weight gain. Since semaglutide delays gastric emptying,...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001070-29 Sponsor Protocol Number: CRF005 Start Date*: 2023-05-26
    Sponsor Name:Chelsea and Westminster NHS Foundation Trust
    Full Title: Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH)
    Medical condition: Human Immunodeficiency Virus (HIV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020441 Human immunodeficiency virus infection, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006416-30 Sponsor Protocol Number: INPAWA 2 Start Date*: 2006-12-28
    Sponsor Name:Unité de Recherches Thérapeutiques
    Full Title: Effect of two distinct dosing regimen of acetaminophen on the anticoagulant effect of warfarin
    Medical condition: Arterial and venous thromboembolic disease including atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043565 Thromboembolic event LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005224-12 Sponsor Protocol Number: KAFTAC2020 Start Date*: 2021-05-01
    Sponsor Name:Haga Teaching Hospital
    Full Title: Elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis using tacrolimus, a drug - drug interaction study
    Medical condition: cystic fibrosis patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007647-14 Sponsor Protocol Number: Nabu1A2 Start Date*: 2009-01-07
    Sponsor Name:Turku University Hospital
    Full Title: The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.
    Medical condition: Pharmacokinetics and pharmacodynamics, healthy volunteer trial
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000985-31 Sponsor Protocol Number: RALAM-II Start Date*: 2017-10-04
    Sponsor Name:Fundació Clinic per a la Recerca Biomédica
    Full Title: Phase 3b, single arm, single site simplification study with dual therapy including 3TC (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected atients experiencing inco...
    Medical condition: Virologically suppressed Human Immunodeficiency Virus-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020168 10020445 Human immunodeficiency virus type I infection with constitutional disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005381-19 Sponsor Protocol Number: KIT-302-03-01 Start Date*: 2014-05-16
    Sponsor Name:Kitov Pharmaceuticals Ltd
    Full Title: A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001632-64 Sponsor Protocol Number: CLCZ696B2225 Start Date*: 2012-08-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, three-period, single sequence study to evaluate the pharmacokinetic drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension
    Medical condition: mild to moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001659-39 Sponsor Protocol Number: 01010106E Start Date*: 2005-08-13
    Sponsor Name:ZERIA Pharmaceutical Co., Ltd.
    Full Title: A Phase Ib/IIa, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects with Unresectable Advanced Pancreati...
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003017-16 Sponsor Protocol Number: CRAD001C2111 Start Date*: 2007-01-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy
    Medical condition: Lung cancer is one of the most common malignancies in developed countries and accounts for millions of deaths worldwide. Two-thirds of NSCLC patients have advanced disease and are considered incura...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011217-24 Sponsor Protocol Number: E7389-E044-203 Start Date*: 2009-12-03
    Sponsor Name:Eisai Ltd
    Full Title: A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine
    Medical condition: Phase 1 - Advanced and/or metastatic cancer Phase 2 - Advanced and/or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027477 Metastatic carcinoma LLT
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000017-20 Sponsor Protocol Number: ASS-Metamizol-DDI Start Date*: 2018-07-17
    Sponsor Name:Universitäts-Herzzentrum Freiburg • Bad Krozingen
    Full Title: Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole)
    Medical condition: Antithrombotic therapy after surgical replacement of stenotic heart valve by a bioprosthesis or mitral valve repair
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002476-14 Sponsor Protocol Number: MicrobioTac_MPA Start Date*: 2020-08-20
    Sponsor Name:Oslo University Hospital - Rikshospitalet
    Full Title: IMMUNOSUPPRESSIVE DRUGS AND GUT MICROBIOME: PHARMACOKINETIC- AND MICROBIOME DIVERSITY EFFECTS
    Medical condition: Kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000513-39 Sponsor Protocol Number: LIN-interaction-01 Start Date*: 2011-07-27
    Sponsor Name:University Medical Center Groningen
    Full Title: The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients
    Medical condition: Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043148 TB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002942-33 Sponsor Protocol Number: GWEP1428 Start Date*: 2015-10-27
    Sponsor Name:GW Research Ltd
    Full Title: A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003623-37 Sponsor Protocol Number: CAN-PDP Start Date*: 2020-02-12
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: CANnabidiol for Parkinson’s Disease Psychosis
    Medical condition: Parkinson's disease psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10074835 Parkinson's disease psychosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-000229-24 Sponsor Protocol Number: RD.06.SPR.201593 Start Date*: 2021-02-23
    Sponsor Name:Galderma S.A.
    Full Title: An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Moderate-to-severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003520-37 Sponsor Protocol Number: D081DC00008 Start Date*: 2014-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatmen...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) CZ (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005872-29 Sponsor Protocol Number: MORAb-003-004 Start Date*: 2009-09-24
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Plati...
    Medical condition: First relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) GR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 08:02:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA